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TGF-b, IL-10, and arginase 1, make a signiﬁcant contribution to
tumoral immunosuppression [7].
Hepatic damage, including metabolic disorders, is linked to
activation of Kupffer cells (the tissue resident macrophages in
the liver) and other stromal cells, which sustain inﬂammatory
cytokine secretion [10]. These resident cells are also responsive
to inﬂammatory factors and adipokines secreted by adipocytes.
Thus, synergic events can perpetuate a vicious cycle that ampli-
ﬁes inﬂammatory processes, which will sustain both steatosis
and inﬂammation while maintaining macrophage activation
and the associated expression of arginase-1. Altogether, these
events might favour disease progression, worsen hepatic damage
and increase the risk of tumorigenesis.
In this context, we fully agree that a better understanding of
cell autonomous and non-autonomous effects of arginase 1
and/or macrophage polarization could open new therapeutic
horizons for liver diseases, particularly in the setting of NAFLD
and HCC.
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JOURNAL OF HEPATOLOGYProtective effects of moderate alcohol consumption on fatty liver:
A spurious association?
To the Editor:
We read with interest Moriya and colleagues’ [1] paper on the
longitudinal role of alcohol intake in relation to fatty liver. We
were somewhat surprised by their ﬁndings and overall conclu-
sion that light-to-moderate and even higher alcohol intake pro-
tects against developing fatty liver over time. They point out
that several other studies also allege that moderate consumption
is associated with a lower risk of non-alcoholic fatty liver disease
(NAFLD) but acknowledge in their introduction that the apparent
protective effects may be spurious associations induced by
confounding factors. However, their analysis is also prone to a
number of biases that have been well documented in the ﬁeld
of alcohol epidemiology [2,3].
Firstly, their choice of past week non-drinkers as a refer-
ent group is unsound. Past week non-drinkers include a mix-
ture of lifelong abstainers, former drinkers (who may have
quit for multiple reasons, including poor health) and infre-
quent drinkers. This misclassiﬁcation error is known to nega-
tively bias the health status of the aggregate group of non-
drinkers and has been demonstrated to produce protective
effects; studies that actively separate these distinctive non-
drinking groups show none [3]. There is evidence that even
if lifetime abstainers are separated from other non-drinkers
they remain a poor choice of referent category for several
reasons [3,4], including misclassiﬁcation bias and that lifetime
non-drinking may itself be indicative of poor health earlier in
the life-course. Additionally, declines in consumption (includ-
ing reductions to infrequent drinking) are more common
amongst former heavy drinkers [3]. This is a potential source
of bias, even in studies that are able to disentangle less than
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Letters to the Editor
weekly drinkers from lifelong non-drinkers, leading to
spurious beneﬁcial effects of moderate intake being observed.
Combined, these studies indicate that alleged protective
effects of light-to-moderate alcohol intake should be treated
with caution.
Moriya and colleagues [1] provide many possible biological
mechanisms for the protective effect they observe, ranging
from insulin sensitivity to antioxidant agents. However, the
association between alcohol intake and these posited media-
tors share the same limitations noted above with respect to
combining current non-drinkers into a single aggregate group
[2].
Additionally, large scale studies have shown that alcohol
consumption is causally related to obesity [5] and that
obesity is a risk factor for NAFLD [6]. Therefore adjustment
for obesity is likely to have produced biased estimates.
Adjusting for a variable on the causal pathway between
alcohol intake and fatty liver is a form of over adjustment
bias [7] – unless controlled direct causal effects are the
estimate of interest which in this case seems unlikely. This
typically biases estimates towards the null. Applied in this
case, one might imagine that those who consume larger
amounts of alcohol are more likely to become obese [5]
which in turn increases their odds of developing fatty liver
[6], therefore adjustment for obesity may have attenuated
the estimated effect of higher levels of alcohol on fatty liver
development.
While we do not have ultrasonography data to illustrate the
potential impact of these biases with reference to the speciﬁc
outcome used in Moriya and colleagues [1] paper, we have data
on triglycerides, body mass index, waist circumference and
c-glutamyltransferase, which can be used to derive the fatty
liver index (FLI) [8]. The FLI has been shown to be moderately
associated with an increased occurrence of fatty liver on ultra-
sonography (scores of P60). In Fig. 1 we show that amongst
3531 men participating in the two most recent data collection
phases (2007–2009 and 2012–2013) of the Whitehall II prospec-
tive cohort study [9], when the group of non-drinkers is decom-
posed further, never drinkers have similar odds of fatty liver
approximately 5 years later as those consuming 0.1–69.9 grams
of alcohol on a weekly basis (OR 1.05, CI 0.48–2.27) after
adjustment for age, smoking status and physical activity.
An increased risk is observed amongst former drinkers
(OR 1.43, CI 0.93–2.19) and monthly/special occasion drinkers
(OR 1.37, CI 1.08–1.73) – the two groups with the largestDrinking
category
Never
Former drinker
Monthly/special occasions
0.1-69.9 g/week
70.0-139.9 g/week
140.0-279.9 g/week
≥280 g/week
1.05 (0.48, 2.27)
1.43 (0.93, 2.19)
1.37 (1.08, 1.73)
1.00 (1.00, 1.00)
1.07 (0.88, 1.30)
1.62 (1.32, 1.99)
2.35 (1.72, 3.22)
Odds ratio
(95% CI)
 0.2  0.5    1.0               2.0              3.0              4.0
Fig. 1. Odds ratios and 95% conﬁdence intervals for fatty liver in men in the
Whitehall II Study by drinking category (N = 3531). Adjusted for age, smoking
status and physical activity level.
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like Moriya and colleagues [1], we show that higher levels of
alcohol intake are associated with greater odds of fatty liver
in a dose-dependent manner which is consistent with prior
knowledge and current public health advice to limit alcohol
intake [10].
While it is acknowledged that Moriya and colleagues [1]
give a somewhat more balanced conclusion at the end of their
article that the decision to drink should be tailored to an
individual – this is not reﬂected throughout the rest of the
manuscript. We illustrate that the alleged protective effect of
moderate alcohol intake they describe is likely to be due to a
combination of overadjustment bias and failure to appropri-
ately stratify the current non-drinking group. As such we
would recommend that it is ill-advised to take up light-
to-moderate drinking to prevent fatty liver, or any other
disease for that matter.
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JOURNAL OF HEPATOLOGYReply to: ‘‘Protective effects of moderate alcohol
consumption on fatty liver: A spurious association?’’To the Editor:
We would like to thank Bell et al. for their comments regarding
our recently published article [1]. They suggested some possible
concerns to be considered carefully.
Concerning the possibility that non-drinkers may not always
be lifetime abstainers, it was difﬁcult to separate former drinkers
from lifetime abstainers based on the questionnaire used in the
study. We recognized this limitation and pointed it out in our
previous study [2], although we were unable to do so in our
recent article due to limited space. It is likely that drinkers are
advised to stop drinking because of fatty liver. Actually, 4% of
men and 15% of women drinking at baseline abstained by the
end of the follow-up. However, we have data regarding
the changes in drinking habits during the observation period;
the longitudinal analysis with the generalized estimating equa-
tion can partly take the changes in the drinking status into
account. Bell et al. also suggested that lifetime abstainers might
have had poor health status. Although we cannot rule out the
possibility that such bias may distort the results, the participants
of our study were generally healthy enough to work and we
suppose that the number of those who had health problems
earlier in their life-course, if any, was small enough not to affect
the statistical analyses.
We cited some articles that suggest the possible mecha-
nisms of the inverse association between alcohol consumption
and fatty liver [1]. Bell et al. also expressed concerns regarding
them. Observational studies may have similar limitations; how-
ever, we also cited an experimental study in mice [3], which is
supposed to be free from those limitations. We cited some
more such articles in our previous study [2], although due to
limited space we were unable to cite all of these in our current
article.
Additionally, Bell et al. mentioned the causal relationship
between alcohol consumption and obesity. However, this
association was not observed in our cohort and rather the reverse
was noted; for example, in men, the body mass index values were
signiﬁcantly lower in the drinkers than in the current non-
drinkers (23.4 ± 2.9 kg/m2 vs. 23.8 ± 3.2 kg/m2, p <0.001) and
the prevalence of obesity was lower in the drinkers than in the
current non-drinkers (26.4% vs. 32.5%, p <0.001). Therefore, there
appears to be no rationale concerning overadjustment bias in our
study. However, we re-calculated the odds ratio for fatty liver in
each category of the average weekly alcohol consumption in men
without adjusting for obesity and found similar results to those
obtained after adjusting for obesity, suggesting that there was
almost no impact of taking obesity into consideration on the
results in our cohort (Fig. 1A).
We thank Bell et al. for presenting their data of the Whitehall
II prospective cohort study demonstrating an association
between a higher alcohol intake and greater odds of fatty liver
using the fatty liver index (FLI) [4]. To compare their results with
ours, we again re-calculated the odds ratio for fatty liver in a
similar manner to the analysis by Bell et al.; that is, we analyzed
with drinking 0.1–69.9 g/week as reference and adjusted for age,
smoking status, and regular exercise. As shown in Fig. 1B, the
non-drinker category had a higher risk for fatty liver than
drinking 0.1–69.9 g/week. Since the non-drinker group was a
mixture of former drinkers and lifetime abstainers, it is difﬁcult
to discuss further concerning this relationship. On the other hand,
higher levels of alcohol intake were not associated with greater
odds of fatty liver in our cohort; it was different from the results
by Bell et al. We are not sure whether the discrepancy is due to
the difference in ethnicity or in the modality to assess fatty liver.
Ultrasonography is more reliable than FLI in assessing fatty liver,
since FLI was developed to predict the presence of fatty liver
diagnosed on ultrasonography [4]. Further studies in different
ethnicities with ultrasonographic assessment would be
warranted.
Finally, we have not stated the safety of alcohol consumption
for all individuals nor encouraged alcohol consumption. In our
paper, we simply described the evidence obtained from a
longitudinal analysis showing that alcohol consumption is
inversely associated with fatty liver in a major part of the general
population. However, it is hard to claim a causal relationship
between alcohol consumption and fatty liver, since our study
was observational and not interventional. Moreover, although
we hypothesize that alcohol may have a somewhat protective
effect against fatty liver within a certain threshold and that thisJournal of Hepatology 2015 vol. 62 j 1204–1218 1211
